[Form 3] Black Titan Corp Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Black Titan Corp director Ben-Tzvi Avraham is reporting his initial ownership position. He holds 3,313 Ordinary Shares, all directly owned, plus options over 1,250 and 5,000 Ordinary Shares. Footnotes explain these shares and options were originally issued by Titan Pharmaceuticals under its 2015 Omnibus Equity Incentive Plan and were exchanged one-for-one into Black Titan securities in connection with the business combination that closed on October 1, 2025. No new purchases or sales are reported; this filing primarily records his post-merger holdings.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Ben-Tzvi Avraham

Role Director

Type	Security	Shares	Price	Value
holding	Options to purchase Ordinary Shares	--	--	--
holding	Options to purchase Ordinary Shares	--	--	--
holding	Ordinary Shares $0.001 par Value	--	--	--

Holdings After Transaction: Options to purchase Ordinary Shares — 1,250 shares (Direct); Ordinary Shares $0.001 par Value — 3,313 shares (Direct)

Footnotes (1)

1. These shares were issued by Titan Pharmaceutical Inc.'s ("Titan"), and each share was exchanged for one share of Black Titan Corporation ("Black Titan") in connection with the business combination which closed on October 1, 2025 (the "Merger"). Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on August 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option. Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on September 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ben-Tzvi Avraham

(Last) (First) (Middle)

BLACK TITAN CORP # 8-02 THE BOUSTEADOR,

10 JALAN PJU 7/6, MUTIARA DAMANSARA,

(Street)

SELANGOR DARUL EHSAN

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/01/2025

3. Issuer Name and Ticker or Trading Symbol
Black Titan Corp [ BTTC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares $0.001 par Value(1)	3,313	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to purchase Ordinary Shares	10/01/2025	(2)	See Footnote(2)	1,250	(2)	D
Options to purchase Ordinary Shares	10/01/2025	(3)	See Footnote(3)	5,000	(3)	D

Explanation of Responses:

1. These shares were issued by Titan Pharmaceutical Inc.'s ("Titan"), and each share was exchanged for one share of Black Titan Corporation ("Black Titan") in connection with the business combination which closed on October 1, 2025 (the "Merger").

2. Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on August 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option.

3. Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on September 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option.

	/s/ Avraham Ben-Tzvi	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)